p53 Codon 72 polymorphic variants, loss of allele-specific transcription, and human papilloma virus 16 and/or 18 E6 messenger RNA expression in squamous cell carcinomas of the head and neck

Cancer Epidemiology Biomarkers and Prevention

Volumn 13, Issue 11, 2004, Pages 1805-1809

  Scheckenbach, Kathrin ^a   Lieven, Oliver ^a   Götte, Karl ^b   Bockmühl, Ulrike ^c   Zotz, Rainer ^a   Bier, Henning ^a   Balz, Vera ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c General Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; MESSENGER RNA; PROLINE; PROTEIN P53; VIRUS RNA;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; GENOTYPE; HEAD AND NECK CARCINOMA; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARYNX; PRIORITY JOURNAL; RNA TRANSLATION; SQUAMOUS CELL CARCINOMA; VIRUS TRANSCRIPTION; WART VIRUS;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; POLYMORPHISM, GENETIC; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 8344272073     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Levine A. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
2. Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis - the p53 network. J Cell Sci 2003;116:4077-85.
3. Koumenis C, Alarcon R, Hammond E, et al. Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol 2001;21:1297-310.
4. Pietenpol JA, Stewart ZA. Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis. Toxicology 2002;181-182:475-81.
5. Buchman VL, Chumakov PM, Ninkina MM, Samarina OP, Georgiev GP. A variation in the structure of the protein-coding region of the human p53 gene. Gene 1988;70:245-52.
6. Harris N, Brill E, Shohat O, et al. Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol 1986;6:4650-6.
7. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987;7:961-3.
8. Jin X, Wu X, Roth JA, et al. Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis 1995;16:2205-8.
9. Zehbe I, Voglino G, Wilander E, Genta F, Tommasino M. Codon 72 polymorphism of p53 and its association with cervical cancer. Lancet 1999;54:218-9.
10. Storey A, Thomas M, Kalita A, et al. Role of p53 polymorphism in the development of human papilloma-virus-associated cancer. Nature 1998;393:229-34.
11. Dumont P, Leu JI-J, Della Pietra AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357-65.
12. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999;19:1092-100.
13. Marin MC, Jost CA, Brooks LA, et al. A common polymorphism acts as an intragenic modifier of mutant p53 behavior. Nat Genet 2002;25:47-54.
14. Tada M, Furuuchi K, Kaneda M, et al. Inactivate the remaining p53 allele or the alternate p73 allele? Preferential selection of the p53 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. Carcinogenesis 2001;22:515-7.
15. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 2004;108:196-9.
16. Balz V, Scheckenbach K, Götte K, Bockmühl U, Petersen I, Bier H. Is the inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res 2003;63:1188-91.
17. van Houten VM, Snijders PJ, van den Brekel MW, et al. Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int J Cancer 2001;93:232-5.
18. Williams C, Norberg T, Ahmadian A, et al. Assessment of sequence-based p53 gene analysis in human breast cancer: messenger RNA in comparison with genomic DNA targets. Clin Chem 1998;44:455-62.
19. Hauser U, Balz V, Carey T, Grénman R, Scheckenbach K, Bier H. Reliable detection of p53 mutations in squamous cell carcinomas of the head and neck requires full length sequencing analysis. Head Neck 2002;24:868-73.
20. Beckman G, Birgander R, Själander A, et al. Is p53 polymorphism maintained by natural selection? Hum Hered 1994;44:266-70.
21. Balló H, Koldovsky P, Hoffmann T, et al. Establishment and characterization of four cell lines derived from human head and neck squamous cell carcinomas for an autologous tumor-fibroblast in vitro model. Anticancer Res 1999;19:3827-36.
22. Fan R, Wu M-T, Miller D, et al. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2000;9:1037-42.
23. Shen H, Liu Z, Strom SS, et al. p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. J Invest Dermatol 2003;121:1510-4.
24. Bonafe M, Olivieri F, Mari D, et al. p53 codon 72 polymorphism and longevity: additional data on centenarians from continental Italy and Sardinia. Am J Hum Genet 1999;65:1782-5.
25. Hayes VM, Hofstra RM, Buys CH, Hollema H, van der Zee AG. Homozygous arginine-72 in wild type p53 and risk of cervical cancer. Lancet 1998;352:1756.
26. Hamel N, Black MJ, Ghadirian P, Foulkes WD. No association between p53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck. Br J Cancer 2000;82:757-9.
27. McWilliams JE, Evans AJ, Beer TM, et al. Genetic polymorphisms in head and neck cancer risk. Head Neck 2000;22:609-17.
28. Summersgill KF, Smith EM, Kirchner HL, Haugen TH, Turek LP. P53 polymorphism, human papillomavirus infection in the oral cavity, and oral cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;90:334-9.
29. Shen H, Zheng Y, Sturgis EM, Spitz MR, Wei Q. P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett 2002;183:123-30.
30. Cloos J, Steen I, Timmerman AJ, van der Schans GP, Snow GB, Braakhuis BJ. DNA-damage processing in blood lymphocytes of head and neck squamous cell carcinoma patients is dependent on tumor site. Int J Cancer 1996;68:26-9.
31. Klussmann JP, Weissenborn SJ, Wieland U, et al. Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer 2001;92:2875-84.
32. de Vries N. Second primary tumors in oral and oropharyngeal cancer. Recent Results Cancer Res 1994;134:121-32.
33. Rosenthal AN, Ryan A, Al-Jehani RM, Storey A, Harwood CA, Jacobs IJ. P53 codon 72 polymorphism and risk of cervical cancer in the UK. Lancet 1998;352:871-2.
34. Abba MC, Villaverde LM, Gomez MA, Dulout FN, Laguens MR, Golijow CD. The p53 codon 72 genotypes in HPV infection and cervical disease. Eur J Obstet Gynecol Reprod Biol 2003;109:63-6.
35. Cenci M, French D, Pisani T, et al. p53 polymorphism at codon 72 is not a risk factor for cervical carcinogenesis in central Italy. Anticancer Res 2003;23:1385-7.
36. Nagpal JK, Patnaik S, Das BR. Prevalence of high-risk human papilloma virus types and its association with p53 codon 72 polymorphism in tobacco addicted oral squamous cell carcinoma (OSCC) patients of eastern India. Int J Cancer 2002;97:649-53.
37. Katiyar S, Thelma BK, Murthy NS, et al. Polymorphism of the p53 codon 72 Arg/Pro and the risk of HPV type 16/18-associated cervical and oral cancer in India. Mol Cell Biol 2003;252:117-24.
38. Ritchie JM, Smith EM, Summersgill KF, et al. Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer 2003;104:336-44.
39. Ah-See KW, Cooke TG, Pickford IR, Soutar D, Baimain A. An allelotype of squamous carcinomas of the head and neck using microsatellite markers. Cancer Res 1994;54:1617-21.
40. Gleich LL, Li YQ, Biddinger PW, et al. The loss of heterozygosity in retinoblastoma and p53 suppressor genes as a prognostic indicator for head and neck cancer. Laryngoscope 1996;106:1378-81.
41. Largey JS, Meltzer SJ, Yin J, Norris K, Sauk JJ, Archibald DW. Loss of heterozygosity of p53 in oral cancers demonstrated by polymerase chain reaction. Cancer 1993;71:1933-7.
42. Nawroz H, van der Piet P, Hruban RH, Koch W, Ruppert JM, Sidransky D. Allelotype of head and neck squamous cell carcinoma. Cancer Res 1994;54:1152-5.
43. Ransom DT, Leonard JH, Kearsley JH, et al. Loss of heterozygosity studies in squamous cell carcinomas of the head and neck. Head Neck 1996;18:248-53.
44. Scholnick SB, El-Mofty SK, Shaw ME, et al. Clinical correlations with allelotype in supraglottic squamous cancers. Otolaryngol Head Neck Surg 1998;118:363-70.
45. Götte K, Riedel F, Neubauer J, Schäfer C, Coy FJ, Hörmann K. The relationship between allelic imbalance on 17p, p53 mutation and p53 overexpression in head and neck cancer. Int J Oncol 2001;19:331-6.
46. Brooks LA, Tidy JA, Gusterson B, et al. Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Res 2000;60:6875-7.
47. Di Como CJ, Gaiddon C, Prives C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 1999;19:1438-49.
48. 2-M-phase proteins. Cancer Res 2004;64:1299-306.
49. Pert MR, Alazawi WOF, Roberts I, et al. Acquisition of high level chromosomal instability is associated with integration of human papillomavirus type 16 in cervical keratinocytes. Cancer Res 2004;64:1359-68.